Research Article

Leishmanicidal Activity of Nine Novel Flavonoids from Delphinium staphisagria

Inmaculada Ramírez-Macías,1 Clotilde Marín,1 Jesús G. Díaz,2 María José Rosales,1 Ramón Gutiérrez-Sánchez,3 and Manuel Sánchez-Moreno1

1 Department of Parasitology, University of Granada, Severo Ochoa s/n, 18071 Granada, Spain
2 Departamento de Química Orgánica y Instituto Universitario de Bio-orgánica “Antonio González”, Universidad de La Laguna, 38206 La Laguna, Spain
3 Department of Statistics, University of Granada, Severo Ochoa s/n, 18071 Granada, Spain

Correspondence should be addressed to Manuel Sánchez-Moreno, msanchem@ugr.es

Received 17 January 2012; Accepted 19 February 2012

Copyright © 2012 Inmaculada Ramírez-Macías et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. To evaluate the in vitro leishmanicidal activity of nine flavonoid derivatives from Delphinium staphisagria against L. infantum and L. braziliensis. Design and Methods. The in vitro activity of compounds 1–9 was assayed on extracellular promastigote and axenic amastigote forms and on intracellular amastigote forms of the parasites. Infectivity and cytotoxicity tests were carried on J774.2 macrophage cells using Glucantime as the reference drug. The mechanisms of action were analysed performing metabolite excretion and transmission electronic microscope ultrastructural alteration studies. Results. Nine flavonoids showed leishmanicidal activity against promastigote as well as amastigote forms of Leishmania infantum and L. braziliensis. These compounds were nontoxic to mammalian cells and were effective at similar concentrations up to or lower than that of the reference drug (Glucantime). The results showed that 2′′-acetylpetiolaroside (compound 8) was clearly the most active. Conclusion. This study has demonstrated that flavonoid derivatives are active against L. infantum and L. braziliensis.

1. Introduction

Leishmaniasis is an infection caused by different species of the protozoan genus Leishmania, which is transmitted by dipterans of the genera Phlebotomus in the Old World and Lutzomyia in the New World.

Leishmaniasis represents one of the most significant of a collection of neglected tropical diseases. According to the latest report of the World Health Organization [1], 350 million people in 88 countries are considered at risk of contracting leishmaniasis, and some 2 million new cases occur annually.

Drug treatment for leishmaniasis has been available since the beginning of the 20th Century [1], but only a few drugs have been developed for use and there are numerous drawbacks to each of the treatments. Two pentavalent antimonialies are available (meglumine antimoniate or Glucantime and sodium stibogluconate or pentostan), but they have common side effects such as anorexia, vomiting, nausea, abdominal pain, malaise, and myalgia. They are available in several formulations, which are administered by intravenous infusion, including liposomal amphotericin B, amphotericin B lipid complex, and amphotericin B colloidal dispersion. However, side effects such as fever, chills, rigor and back pain, and transient nephrotoxicity or thrombocytopenia occur in some patients. Other antileishmanial medicines are paromomycin (aminosidine) and pentamidine isethionate, which are usually administered intramuscularly. The alkyl phospholipid (hexadecylphosphocholine), commonly known as miltefosine, induces gastrointestinal side effects such as anorexia, nausea, vomiting (38%) and diarrhea (20%), and also skin allergies, elevated hepatic transaminase concentrations, and, occasionally, renal failure. It is now used in combination with different classes of azole oral antifungal agents including ketoconazole, fluconazole, and itraconazole.

In addition to the adverse effects of the drugs, resistance to these treatments is appearing in the parasites. For all these
reasons, further novel drug development is necessary to treat these infections. Considerable attention is currently being paid to phytotherapy in the search for new drugs. One method used to discover new drugs is to investigate natural products from plants used medicinally [2]. The broad range of plant families and species available offers many potentially active leishmanicidal substances [3, 4]. Leishmanicidal capacity of alkaloid compounds isolated from medicinal plants has been studied [5], and the antileishmania capacity of Aloe Vera exudate against L. donovani has been established [6].

Leishmanicidal properties may arise in phytochemicals such as flavonoids, which are hence strong candidates for use in combination therapy against these infections. Flavonoids are abundant in fruits, vegetables, and saps of plants and are demonstrated to have anticarcinogenic, antimicrobial, and antiparasitic activity [7, 8]. Flavonoid analogues derived from Consolida oliveriana exerted a significant effect on the in vitro growth of species of Leishmania spp. [9].

In this work, the inhibitory effects of flavonoids from aerial parts of Delphinium staphisagria (L. (Ranunculaceae) on the extracellular and intracellular stages of L. infantum and L. braziliensis were investigated. In addition, the cytotoxic effects of these compounds against a host cell line were assessed. We also used 1H-NMR spectroscopic analysis to determine the nature and percentage of the excretion metabolites and to elucidate any inhibitory effect that the compounds have on the glycolytic pathway. Finally, the effects of the compounds on the ultrastructure were studied.

2. Material and Methods

2.1. Plant Material. Aerial parts of the Delphinium staphisagria were collected and processed as described previously Díaz et al. [10]. Nine flavonoids (1–9) were isolated, derivatized, and identified (Figure 1) [10].

2.2. Parasite Strain and Culture. L. infantum (MCAN/ES/2001/UCM-10) and L. braziliensis (MHOM/BR/1975/M2904) were cultivated in vitro in trypanosomes liquid medium (MTL) with 10% inactive fetal bovine serum and were kept in an air atmosphere at 28°C, in Roux flasks (Corning, USA) with a surface area of 75 cm², according to the methodology described by González et al. [4].

2.3. Cell Culture and Cytotoxicity Tests. J774.2 macrophages (ECACC number 91051511) were originally obtained from a tumour in a female BALB/c rat in 1968. The cytotoxicity test for macrophages was performed according to the methodology of González et al. [4]. After 72 hours of treatment, cell viability was determined by flow cytometry. Thus, 100 μL/well of propidium iodide solution (100 mg/mL) was added and incubated for 10 min at 28°C in darkness. Afterwards, 100 μL/well of fluorescein diacetate (100 ng/mL) was added and incubated under the same conditions. Finally, the cells were recovered by centrifugation at 400 g for 10 min and the precipitate washed with phosphate buffered saline (PBS). Flow cytometric analysis was performed with a FACSVantage flow cytometer (Becton Dickinson). The percentage viability was calculated in comparison with the control culture. The IC50 was calculated using linear regression analysis from the Kc values of the concentrations employed.

2.4. In Vitro Activity Assay

2.4.1. Promastigote Forms, Assay. The compounds obtained were dissolved in the culture medium, at dosages of 100, 50, 25, 10, and 1 μM. The effects of each compound against promastigote forms were tested at 72 hours using a Neubauer haemocytometric chamber. The antileishmanial effect is expressed as the IC50, that is, the concentration required to give 50% inhibition, calculated by linear regression analysis from the Kc values of the concentrations employed.

2.4.2. Amastigote Forms, Assay. J774.2 macrophages were grown in minimum essential medium (MEM) plus glutamine (2 mM), supplemented with 20% inactive fetal bovine serum, and were kept in a humidified atmosphere of 95% air and 5% CO2 at 37°C.

Cells were seeded at a density of 1 × 10⁴ cells/well in 24-well microplates (Nunc) with rounded coverslips on the bottom and cultured for 2 days. Afterwards the cells were infected in vitro with promastigote forms of L. infantum and L. braziliensis, at a ratio of 10:1 during 24 hours. The non-phagocytosed parasites were removed by washing, and then the drugs (at 1, 10, 25, 50, 100 μM) were added. Macrophages with the drugs were incubated for 72 hours at 37°C in 5% CO2.

Drug activity was determined on the basis of number of amastigotes in treated and untreated cultures in methanol-fixed and Giemsa-stained preparations. The number of amastigotes was determined by analyzing 200 host cells distributed in randomly chosen microscopic fields. The antileishmanial effect is expressed as the IC50 values are the means of three separate determinations.

2.4.3. Axenic Amastigote Forms, Assay. Axenic amastigotes forms of L. infantum and L. braziliensis were cultured following the methodology described previously by Moreno et al. [11]. Thus, promastigote transformation to amastigotes was obtained after three days of culture in M199 medium (Invitrogen, Leiden, The Netherlands) supplemented with 10% heat-inactivated FCS, 1 g/L β-alanine, 100 mg/L L-asparagine, 200 mg/L sacarose, 50 mg/L sodium pyruvate, 320 mg/L malic acid, 40 mg/L fumaric acid, 70 mg/L succinic acid, 200 mg/L α-ketoglutaric acid, 300 mg/L citric acid, 1.1 g/L sodium bicarbonate, 5 g/L MES, 0.4 mg/L hemin, and 10 mg/L gentamicin pH 5.4 at 37°C. The effect of each compound against axenic amastigotes forms was tested at 48 hours using a Neubauer haemocytometric chamber. The antileishmanial effect is expressed as the IC50.

2.5. Infection Assay. J774.2 macrophage cells were grown under the same conditions expressed in amastigote forms assay during two days. Afterwards, the cells were infected in
vitro with promastigote forms of L. infantum and L. braziliensis, at a ratio of 10:1. The drugs (IC_{25} concentrations) were added immediately after infection and were incubated for 12 hours at 37°C in 5% CO_{2}. The nonphagocytosed parasites and the drugs were removed by washing, and then the infected cultures were grown for 10 days in fresh medium. Fresh culture medium was added every 48 h. The drug activity was determined from the percentage of infected cells and the number of amastigotes per infected cell (in treated and untreated cultures) in methanol-fixed and Giemsa-stained preparations. The percentage of infected cells and the mean number of amastigotes per infected cell were determined by analyzing 200 host cells distributed in randomly chosen microscopic fields. Values are the average of three separate determinations.

2.6. Metabolite Excretion. Cultures of L. infantum and L. braziliensis promastigotes (initial concentration 5 × 10^{5} cells/mL) received IC_{25} concentrations of the compounds (except for control cultures). After incubation for 96 hours at 28°C, the cells were centrifuged at 400 g for 10 min. Then supernatants were collected to determine the excreted metabolites using 1H-NMR, and, eventually, chemical displacements were expressed in parts per million (ppm), using sodium 2,2-dimethyl-2-silapentane-5-sulphonate as the reference signal. The chemical displacements used to identify the respective metabolites were consistent with those described by Fernández-Becerra et al. [12]

2.7. Ultrastructural Alterations. The parasites were cultured at a density of 5 × 10^{5} cells/mL in MTL medium, and the cultures contained drugs at the IC_{25} concentration.

After 96 hours, those cultures were centrifuged at 400 g for 10 min, and the pellets produced were washed in PBS and then mixed with 2% (v/v) P-formaldehyde-glutaraldehyde in 0.05 M cacodylate buffer (pH 7.4) for 4 hours at 4°C. After that, the pellets were prepared for TEM employing the technique of González et al. [4].

3. Results

3.1. In Vitro Antileishmanial Evaluation. The IC_{50} values obtained on promastigote, axenic amastigote, and intracellular amastigote forms of L. infantum and L. braziliensis after 72 h of exposure with compounds 1–9 are displayed in the first three columns of Table 1. Values of the reference drug, Glucantime, are also included for all cases for comparison.

The antileishmanial activity in both extra- and intracellular forms is similar or, in most cases, less than that found for Glucantime, with the compounds 7, 8, and 9 presenting the lowest IC_{50}. After 96 hours, those cultures were centrifuged at 400 g for 10 min, and the pellets produced were washed in PBS and then mixed with 2% (v/v) P-formaldehyde-glutaraldehyde in 0.05 M cacodylate buffer (pH 7.4) for 4 hours at 4°C. After that, the pellets were prepared for TEM employing the technique of González et al. [4].
Table 1: In vitro activity, toxicity, and selectivity index found for the astragalin-based (1-3), paeonoside-based (4-6), and petiolaroside-based (7-9) derivatives on extracellular and intracellular forms of *Leishmania* spp.

(a) *Leishmania infantum*

| Compounds | Promastigote forms | Activity IC$_{50}$ (µM)$^a$ | Promastigote forms | bMacrophage toxicity IC$_{50}$ | Promastigote forms | bMacrophage toxicity IC$_{50}$ |
|-----------|--------------------|-----------------------------|--------------------|------------------------------|--------------------|------------------------------|
|           |                    | Axenic amastigote forms     | Intracellular amastigote forms |                | Axenic amastigote forms | Intracellular amastigote forms |
| Glucantime| 18.0 ± 3.1         | 24.2 ± 2.6                  | 30.0 ± 2.7          | 15.2 ± 1.3                   | 0.8                | 0.6                          |
| 1         | 35.1 ± 3.3         | 29.2 ± 2.8                  | 45.9 ± 2.7          | 235.9 ± 17.9                 | 6.7 (8)            | 8.1 (14)                     |
| 2         | 34.1 ± 1.6         | 32.7 ± 5.0                  | 42.3 ± 3.9          | 267.0 ± 11.0                 | 7.8 (10)           | 8.2 (14)                     |
| 3         | 40.4 ± 3.4         | 29.2 ± 3.1                  | 38.1 ± 1.6          | 350.6 ± 26.8                 | 8.7 (11)           | 12.0 (20)                    |
| 4         | 25.1 ± 1.9         | 26.9 ± 1.4                  | 31.4 ± 2.0          | >1000.0 ± 60.0               | 39.8 (50)          | 37.2 (62)                    |
| 5         | 24.6 ± 3.7         | 29.8 ± 2.2                  | 37.2 ± 3.5          | >1000.0 ± 71.4               | 40.7 (51)          | 33.6 (56)                    |
| 6         | 23.1 ± 4.6         | 30.5 ± 2.3                  | 40.3 ± 2.4          | >1000.0 ± 82.0               | 43.3 (54)          | 32.8 (55)                    |
| 7         | 24.5 ± 1.1         | 19.4 ± 1.4                  | 27.8 ± 1.4          | >1000.0 ± 55.6               | 40.8 (51)          | 51.5 (56)                    |
| 8         | 19.1 ± 0.9         | 18.4 ± 1.3                  | 32.1 ± 2.0          | >1000.0 ± 38.9               | 52.4 (66)          | 54.3 (91)                    |
| 9         | 22.8 ± 1.7         | 21.5 ± 0.9                  | 31.0 ± 1.7          | 489.8 ± 22.4                 | 21.5 (27)          | 22.8 (38)                    |

(b) *Leishmania braziliensis*

| Compounds | Promastigote forms | Activity IC$_{50}$ (µM)$^a$ | Promastigote forms | bMacrophage toxicity IC$_{50}$ | Promastigote forms | bMacrophage toxicity IC$_{50}$ |
|-----------|--------------------|-----------------------------|--------------------|------------------------------|--------------------|------------------------------|
|           |                    | Axenic amastigote forms     | Intracellular amastigote forms |                | Axenic amastigote forms | Intracellular amastigote forms |
| Glucantime| 25.6 ± 1.6         | 30.4 ± 6.1                  | 31.1 ± 3.0          | 15.2 ± 1.3                   | 0.6                | 0.5                          |
| 1         | 28.1 ± 1.0         | 22.6 ± 1.7                  | 32.2 ± 1.6          | 235.9 ± 17.9                 | 8.4 (14)           | 10.4 (21)                    |
| 2         | 25.1 ± 2.5         | 27.9 ± 2.7                  | 30.2 ± 3.8          | 267.0 ± 11.0                 | 10.6 (18)          | 9.6 (19)                     |
| 3         | 28.4 ± 3.0         | 32.9 ± 3.0                  | 41.9 ± 4.0          | 350.6 ± 26.8                 | 12.3 (21)          | 10.7 (21)                    |
| 4         | 28.1 ± 5.2         | 23.7 ± 2.1                  | 32.7 ± 2.1          | >1000.0 ± 60.0               | 35.6 (59)          | 42.2 (84)                    |
| 5         | 34.1 ± 6.6         | 19.4 ± 0.9                  | 50.9 ± 6.2          | >1000.0 ± 71.4               | 29.3 (49)          | 51.5 (103)                   |
| 6         | 31.3 ± 3.0         | 28.0 ± 1.6                  | 30.4 ± 2.7          | >1000.0 ± 82.0               | 31.9 (53)          | 35.7 (71)                    |
| 7         | 21.1 ± 1.7         | 19.5 ± 0.8                  | 33.9 ± 3.5          | >1000.0 ± 55.6               | 47.4 (79)          | 51.3 (103)                   |
| 8         | 29.0 ± 1.5         | 25.5 ± 0.7                  | 20.1 ± 1.7          | >1000.0 ± 38.9               | 34.5 (58)          | 39.2 (78)                    |
| 9         | 32.3 ± 3.3         | 24.6 ± 1.3                  | 21.0 ± 1.3          | 489.8 ± 22.4                 | 15.2 (25)          | 19.9 (40)                    |

Results are averages of three separate determinations.

$^a$IC$_{50}$ = the concentration required to give 50% inhibition, calculated by linear regression analysis from the Kc values at concentrations employed (1, 10, 25, 50, and 100 µM).

$^b$Against J774.2 macrophages after 72 h of culture.

$^c$Selectivity index = IC$_{50}$ macrophages/IC$_{50}$ extracellular and intracellular form of the parasite. In brackets: number of times that compound SI exceeds the reference drug SI.
Figure 2: Effects of flavonoids 4, 5, 6, 7, and 8 on the infection and growth rates of Leishmania spp. (a) rate of infection of L. infantum; (c) mean number of amastigotes per infected J774 A.2 macrophage cells of L. infantum; (b) rate of infection of L. braziliensis; (d) mean number of amastigotes per infected J774 A.2 macrophage cells of L. braziliensis. (-▲-, control; -△-, comp. 4; -▼-, comp. 5; -□-, comp. 6; -♦-, comp. 7; -∇-, comp. 8; -○-, Glucantime). At IC_{25} conc., values are means of three separate experiments.

Illustrative of the in vitro potential of the compounds tested with respect to the reference drug. Compounds 7, 8, 4, 5, and 6 showed the best SI for L. infantum (Table 1(a)), with indexes exceeding that of the reference drug SI by more than 50 times. Compounds 1, 2, 3, and 9 were more effective than Glucantime; however, SI values of 50 times or greater were not reached, which is the criterion for a compound to be included in subsequent studies [13].

Similar results can be extracted from the L. braziliensis data shown in Table 1(b). The compounds 7, 8, 4, and 6 again gave the best SI results in the three assays performed, with values exceeding those of the reference drugs by 79, 103, and 59 times in the case of compound 7, by 58, 78, and 100 times for compound 8, by 59, 84, and 61 times for compound 4, and by 53, 71, and 66 times for compound 6. Although compound 5 did not give SI values greater than or equal to 50 times those of the reference drugs, it was included in subsequent studies because promastigote and intracellular amastigote SI values were close to 50 times that of the reference drug, while the axenic amastigote SI was two times (Table 1(b)).

The effectiveness of the compounds on the infection rate and the intracellular replication of the amastigote forms was determined by the infection assay (Figure 2). When selected flavonoid compounds 4–8 and Glucantime were added at their respective IC_{25} concentrations to macrophages infected with Leishmania spp. promastigote forms, the infection rate decreased significantly after 12 h with respect to the control measurement. The infection rate decreases followed the trend 8 > 5 > 7 = 4 > 6 for L. infantum (Figure 2(a)) and 8 > 6 > 5 > 7 > 4 for L. braziliensis (Figure 2(b)) with percentages of inhibition capacity of 95%, 79%, 77%, and 71%, respectively, in the case of L. infantum and 88%, 82%, 79%, 69%, and 68%, respectively, in the case of L. braziliensis. These values are remarkably higher than those for inhibition by Glucantime (63% and 58% for L. infantum and L. braziliensis, resp.).
All five compounds were more effective than Glucantime (only 12% decrease for L. infantum and 33% decrease for L. braziliensis) at decreasing the average number of amastigotes per infected macrophage cells (Figures 2(c) and 2(d)). Compound 8 was the most effective in L. infantum and L. braziliensis. The amastigote number decreases measured were as follows: 8 (78%) > 7 (49%) > 5 (45%) > 4 (37%) > 6 (24%) for L. infantum and 8 (82%) > 5 (72%) > 6 (69%) > 4 (61%) > 7 (55%) for L. braziliensis.

3.2. Metabolites Excretion Effect. After treatment of the parasites with compounds 4–8 at IC_{25}, the excretion of the catabolites was clearly altered. Figure 3 displays the modifications observed in the height of the spectra peaks corresponding to the most representative final excretion products. From a careful examination of the data, it would appear that there are marked differences in the catabolic pathway. In the case of L. infantum, compounds 4, 5, 6, and 8 gave similar spectra, with an increase in the excretion of succinate, and acetate, followed by malate, alanine, lactate, and ethanol. On the other hand, compound 7 causes an increase in the production of malate, succinate, ethanol, and lactate, but a decrease of excreted acetate and alanine levels (Figure 3(a)).

In the case of L. braziliensis, the increase of excreted succinate was the most significant change when the parasites were treated with the compounds. Compounds 6, 7, and 8 caused decreases in the excretion of acetate (Figure 3(b)).

3.3. Ultrastructural Alterations. The transmission electron microscope evaluation of flavonoid compounds 4–8 against Leishmania spp. promastigotes showed notable ultrastructural alterations, as reflected in Figures 4 and 5 (panels b, c, d, e) with respect to the control (Figures 4(a) and 5(a)). All compounds produced significant alterations to L. infantum, but the compounds most effective were 4 and 8, as illustrated in Figures 4(b) and 4(e). All of the compounds induced the formation of strongly electrondense inclusions that appeared inside and outside vacuoles with different sizes, or directly in the cell cytoplasm. The major effect of compound 8 was that many of the parasites adopted distorted shapes with distorted cytoplasm, while no cytoplasmic organelles were visible due to the altered appearance of promastigotes. However, large vacuoles containing cellular debris were visible. With compound 4 (Figure 4(b)), many of the parasites appeared dead, while another showed pronounced vacuolization, and many of these vacuoles contained strongly electrodense inclusions. Compound 5 produced similar effects (Figure 4(c)). In the same way, compound 6 induced empty vacuoles, lipid vacuoles, and a large number of electrodense vesicles (Figure 4(d)). By contrast, compound 7 showed no induction of substantial alterations (graph not shown).

Studies of ultrastructural alterations made on L. braziliensis showed that the compounds produced changes similar to those they produced in L. infantum. Another effect of the compounds was the expansion of the kinetoplast, which appeared swollen when treated with compound 4 (Figure 5(b)). Compound 8 (Figure 5(e)) induced changes in the shape of parasites, with them showing completely altered forms. All these changes occurred after treatment with compound 7 (Figure 5(d)), while compound 5 produced no significant changes compared to the control (data not shown).

4. Discussion

Many people living in rural areas have no easy access to conventional allopathic treatments, largely due to the limited
Figure 4: Ultrastructural alterations by TEM in *L. infantum* treated with the flavonoid derivatives. (a) Control parasite of *L. infantum* showing organelles with their characteristic features such as the nucleus (N), kinetoplast (K), reservosomes (R), mitochondrion (M), and vacuoles (V) (bar: 1 μm). (b) *L. infantum* treated with compound 4. Electrodense organelles (arrow) (Bar: 1 μm). (c) *L. infantum* treated with compound 5 with intense vacuolization (V) (Bar: 1.59 μm). (d) *L. infantum* treated with compound 6, vacuoles (V), lipid vacuoles (LV), and electrodense vesicles (arrow) (bar: 1.59 μm). (e) *L. infantum* treated with compound 8 with distorted parasites (arrow) (Bar: 1 μm).
availability of health services and their low socioeconomic status. Therefore, plants may provide an important and necessary source of therapeutic medicinal compounds. Flavones and their derivatives, flavonoids and flavonols, are among the most attractive plant derivatives that might enrich the current therapy options, due to their extremely large range of biological properties [14].

In this study, *in vitro* biological activity of nine flavonoid compounds against extracellular and intracellular forms *Leishmania* spp. was investigated. This is important as many
studies of the activity of compounds against *Leishmania* spp. are performed on promastigote forms, which are much easier to work in *in vitro*. However, since extracellular forms are not the developed forms of the parasite in vertebrate hosts, evaluations made with these forms are merely indicative of the potential leishmanicidal activity of the compounds tested. Consequently, a preliminary test using extracellular promastigote forms should always be complemented by a subsequent evaluation using intracellular forms (amastigotes in vertebrate host cells), so that a better understanding of the activity may be obtained [4].

The petiolaroside-based derivatives (7–9) presented the lowest IC$_{50}$ values against extra- and intracellular forms.

Previously, the nine flavonoids investigated here were tested against epimastigote forms of *Trypanosoma cruzi*, and the most effective compounds were astragalin (1) and two acetylated derivatives (2 and 3). These had significantly lower IC$_{50}$ values compared with benznidazole [15]. By contrast, in this study, we saw that the astragalin and its derivates were the least effective agents against *Leishmania* spp.

Petiolaroside, 2''-acetylpetiolaroside (7 and 8, resp.), and paenoside and its derivates (4, 5, and 6) showed the best selectivity indexes. These indexes exceeded the reference drug SI by more than 50 times. The astragalin and its derivates (1, 2, and 3) and petiolaroside decacetate (9) were all more effective than Glucantime. If we compare the results obtained for the infection rate and the number of amastigotes per infected macrophage cells for both *Leishmania* species, it can be concluded that 2''-acetylpetiolaroside (8) is clearly the most active. The acetylated derivatives 2''-acetylpetiolaroside (8) and 2''-acetylpaeonoside (5) are more active than petiolaroside (7) and paenoside (4), respectively.

As far as is known to date, none of the trypansomatids studied are capable of completely degrading glucose to CO$_2$ under aerobic conditions. When this occurs, it results in the excretion of a major part of the carbon skeleton into the medium as fermented metabolites, which can differ according to the employed species [16]. $^1$H-NMR spectra enabled us to determine the fermented metabolites excreted by the parasites during their *in vitro* culture. The final products of glucose catabolism in *Leishmania* are usually CO$_2$, succinate, acetate, L-lactate, pyruvate, L-alanine, and ethanol [17]. As with *T. cruzi* [18], one of the major metabolites excreted by *Leishmania* spp. is succinate, with the main role likely to be to maintain the glycosomal redox balance by providing two glycosomal oxidoreductase enzymes. These enzymes allow reoxidation of NADH produced by glyceraldehyde-3-phosphate dehydrogenase in the glycolytic pathway. Succinic fermentation offers one significant advantage as it requires only half the produced phosphoenolpyruvate (PEP) to maintain the NAD+/NADH balance. The remaining PEP is converted to acetate, depending on the species under consideration.

The majority of metabolites excreted by *L. infantum* are succinate and acetate. In the case of *L. infantum*, variations in the final catabolism products seem to be dependent on the structural aspects of the compounds assayed. These data agree well with those of other authors [18].

Analyses of *in vitro* and *in vivo* results of *Trypanosoma cruzi* showed that the best potential flavonoids to treat Chagas disease were the acetylated compounds 2, 5, and 6 [15]. The present work confirmed this conclusion in the case of visceral leishmaniasis (*L. infantum*) and mucocutaneous leishmaniasis (*L. braziliensis*). Moreover, these data are consistent with others previously published, which showed that several acetylated flavonoids derived from *Consolida oliveriana* were very active *in vitro* against both extracellular and intracellular forms of *L. (V.) peruviana* and *L. (V.) braziliensis* [9].

In conclusion, this study has demonstrated that flavonoid derivatives are active against *L. infantum* and *L. braziliensis*. These results support further investigation of flavonoid compounds as potential agents against Leishmaniasis.

Acknowledgments

The authors would like to express their thanks to M. J. Martínez-Guerrero, J. Lazúa-Alcón and E. Onorato-Gutiérrez for their expert technical help in transmission electron microscopy, flow cytometry and nuclear magnetic resonance spectroscopy, respectively. They also appreciate the help of E. Guerrero López and C. Anaya Romero in culture media preparation and *in vitro* culture. This work was financially supported by the Consolider Ingenio Project CSD2010-00065 (Spain).

References

[1] “Control of the leishmaniases,” WHO Technical Report 949, World Health Organization, Geneva, Switzerland, 2010.

[2] O. Kayser, A. F. Kiderlen, and S. L. Croft, “Natural products as antiparasitic drugs,” *Parasitology Research*, vol. 90, no. 2, pp. S55–S62, 2003.

[3] M. J. Chan-Bacab and L. M. Peña-Rodríguez, “Plant natural products with leishmanicidal activity,” *Natural Product Reports*, vol. 18, no. 6, pp. 674–688, 2001.

[4] P. González, C. Marin, I. Rodríguez-González et al., “*In vitro* activity of C20-diterpenoid alkaloid derivatives in promastigotes and intracellular amastigotes of *Leishmania infantum*,” *International Journal of Antimicrobial Agents*, vol. 25, no. 2, pp. 136–141, 2005.

[5] C. Di Giorgio, F. Delmas, E. Ollivier, R. Elias, G. Balansard, and P. Timon-David, “*In vitro* activity of the β-carboline alkaloids harmane, harmine, and harmaline toward parasites of the species *Leishmania infantum*,” *Experimental Parasitology*, vol. 106, no. 3–4, pp. 67–74, 2004.

[6] A. Dutta, S. Bandyopadhyay, C. Mandal, and M. Chatterjee, “Aloe vera leaf exudate induces a caspase-independent cell death in *Leishmania donovani* promastigotes,” *Journal of Medical Microbiology*, vol. 56, no. 5, pp. 629–636, 2007.

[7] D. J. Newman and G. M. Cragg, “Natural products as sources of new drugs over the last 25 years,” *Journal of Natural Products*, vol. 70, no. 3, pp. 461–477, 2007.

[8] F. Torres, J. Quintana, J. G. Diaz, A. J. Carmona, and F. Estévez, “*Trifolin* acetate-induced cell death in human leukemia cells is dependent on caspase-6 and activates the MAPK pathway,” *Aptoptosis*, vol. 13, no. 5, pp. 716–728, 2008.

[9] C. Marin, S. Boutaleb-Charki, J. G. Diaz et al., “Antileishmaniasis activity of flavonoids from *Consolida oliveriana*,” *Journal of Natural Products*, vol. 72, no. 6, pp. 1069–1074, 2009.
[10] J. G. Díaz, A. J. Carmona, P. P. de Paz, and W. Herz, "Acylated flavonol glycosides from Delphinium staphisagria," *Phytochemistry Letters*, vol. 1, no. 2, pp. 125–129, 2008.

[11] D. Moreno, D. Plano, Y. Baquedano, A. Jiménez-Ruiz, J. Antonio Palop, and C. Sanmartín, "Antileishmanial activity of imidothiocarbamates and imidoselenocarbamates," *Parasitology Research*, vol. 108, no. 1, pp. 233–239, 2011.

[12] C. Fernández-Becerra, M. Sánchez-Moreno, A. Osuna, and F. R. Opperdoes, "Comparative aspects of energy metabolism in plant trypanosomatids," *Journal of Eukaryotic Microbiology*, vol. 44, no. 5, pp. 523–529, 1997.

[13] S. Nwaka and A. Hudson, "Innovative lead discovery strategies for tropical diseases," *Nature Reviews Drug Discovery*, vol. 5, no. 11, pp. 941–955, 2006.

[14] L. H. Cazarolli, L. Zanatta, E. H. Alberton et al., "Flavonoids: prospective drug candidates," *Mini Reviews in Medicinal Chemistry*, vol. 8, no. 13, pp. 1429–1440, 2008.

[15] C. Marín, I. Ramírez-Macías, A. López-Céspedes et al., "In vitro and in vivo trypanocidal activity of flavonoids from Delphinium staphisagria against chagas disease," *Journal of Natural Products*, vol. 74, no. 4, pp. 744–750, 2011.

[16] F. Bringaud, L. Rivière, and V. Coustou, "Energy metabolism of trypanosomatids: adaptation to available carbon sources," *Molecular and Biochemical Parasitology*, vol. 149, no. 1, pp. 1–9, 2006.

[17] J. J. Cazzulo, "Aerobic fermentation of glucose by trypanosomatids," *FASEB Journal*, vol. 6, no. 13, pp. 3153–3161, 1992.

[18] M. L. Ginger, "Trypanosomatid biology and euglenozoan evolution: new insights and shifting paradigms revealed through genome sequencing," *Protist*, vol. 156, no. 4, pp. 377–392, 2005.